Last reviewed · How we verify

Candesartan cilexetil / hydrochlorothiazide

Takeda · FDA-approved active Small molecule

Candesartan cilexetil / hydrochlorothiazide is a Angiotensin II receptor antagonist / thiazide diuretic combination Small molecule drug developed by Takeda. It is currently FDA-approved for Hypertension, Reduction of cardiovascular risk in hypertensive patients. Also known as: ECARD® Combination Tablets LD&HD.

Candesartan cilexetil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.

Candesartan cilexetil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume. Used for Hypertension, Reduction of cardiovascular risk in hypertensive patients.

At a glance

Generic nameCandesartan cilexetil / hydrochlorothiazide
Also known asECARD® Combination Tablets LD&HD
SponsorTakeda
Drug classAngiotensin II receptor antagonist / thiazide diuretic combination
TargetAT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Candesartan cilexetil is a prodrug that is converted to candesartan, an angiotensin II receptor antagonist (ARB) that selectively blocks AT1 receptors, preventing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting sodium and water excretion to reduce blood volume. The combination provides complementary antihypertensive effects through different mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Candesartan cilexetil / hydrochlorothiazide

What is Candesartan cilexetil / hydrochlorothiazide?

Candesartan cilexetil / hydrochlorothiazide is a Angiotensin II receptor antagonist / thiazide diuretic combination drug developed by Takeda, indicated for Hypertension, Reduction of cardiovascular risk in hypertensive patients.

How does Candesartan cilexetil / hydrochlorothiazide work?

Candesartan cilexetil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.

What is Candesartan cilexetil / hydrochlorothiazide used for?

Candesartan cilexetil / hydrochlorothiazide is indicated for Hypertension, Reduction of cardiovascular risk in hypertensive patients.

Who makes Candesartan cilexetil / hydrochlorothiazide?

Candesartan cilexetil / hydrochlorothiazide is developed and marketed by Takeda (see full Takeda pipeline at /company/takeda).

Is Candesartan cilexetil / hydrochlorothiazide also known as anything else?

Candesartan cilexetil / hydrochlorothiazide is also known as ECARD® Combination Tablets LD&HD.

What drug class is Candesartan cilexetil / hydrochlorothiazide in?

Candesartan cilexetil / hydrochlorothiazide belongs to the Angiotensin II receptor antagonist / thiazide diuretic combination class. See all Angiotensin II receptor antagonist / thiazide diuretic combination drugs at /class/angiotensin-ii-receptor-antagonist-thiazide-diuretic-combination.

What development phase is Candesartan cilexetil / hydrochlorothiazide in?

Candesartan cilexetil / hydrochlorothiazide is FDA-approved (marketed).

What are the side effects of Candesartan cilexetil / hydrochlorothiazide?

Common side effects of Candesartan cilexetil / hydrochlorothiazide include Dizziness, Hyperkalemia, Hypokalemia, Headache, Fatigue, Cough.

What does Candesartan cilexetil / hydrochlorothiazide target?

Candesartan cilexetil / hydrochlorothiazide targets AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter and is a Angiotensin II receptor antagonist / thiazide diuretic combination.

Related